论文部分内容阅读
目的:探讨p65在原发性上皮性卵巢癌的表达及临床意义。方法:选择我院2010年1月至2015年12月收治的70例原发性上皮性卵巢癌患者、10例交界恶性上皮性卵巢肿瘤患者及15例健康体检者,采用免疫组织化学SP法对3组卵巢组织中p65的表达进行检测,分析其表达与上皮性卵巢癌的发生、发展的关系。结果:p65在正常卵巢组织、原发性上皮性卵巢癌及交界恶性卵巢肿瘤中阳性表达主要位于细胞核;原发性上皮性卵巢癌临床分期和分化程度越高,p65阳性表达率越高;p65在正常卵巢组织、原发性上皮性卵巢癌及交界恶性卵巢肿瘤中的阳性表达率比较差异有显著性(P<0.05)。结论:p65与原发性上皮性卵巢癌的发生有关,p65的高表达提示预后不良。
Objective: To investigate the expression of p65 in primary epithelial ovarian cancer and its clinical significance. Methods: Seventy patients with primary epithelial ovarian cancer, 10 patients with borderline malignant ovarian tumor and 15 healthy controls were selected from January 2010 to December 2015 in our hospital. Immunohistochemistry The expression of p65 in 3 groups of ovarian tissues was detected, and its relationship with the occurrence and development of epithelial ovarian cancer was analyzed. Results: The positive expression of p65 in normal ovarian tissues, primary epithelial ovarian cancer and borderline malignant ovarian tumors was mainly located in the nucleus. The higher the clinical stage and degree of differentiation, the higher the positive rate of p65 was. P65 The positive expression rate in normal ovarian tissue, primary epithelial ovarian cancer and borderline malignant ovarian tumor was significantly different (P <0.05). Conclusion: p65 is associated with the occurrence of primary epithelial ovarian cancer. The high expression of p65 suggests a poor prognosis.